Safety and Activity of a Dose-Dense Short-Term Chemoimmunotherapy in HIV-Positive Patients with Burkitt Lymphoma (HIV-BL pts): Final Results of the Carmen Phase II Trial

被引：0
|
作者：
Ferreri, Andres J. M.
Spina, Michele
Cattaneo, Chiara
Verga, Luisa
Allione, Bernardino
Ferrari, Daris
Rigacci, Luigi
Fumagalli, Luca
Donadoni, Giovanni
Lleshi, Arben
Sassone, Marianna
Rossi, Giuseppe
Re, Alessandro
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2828
引用
收藏
页数：3
相关论文
共 13 条
  • [1] Safety and Activity of Intensive Short-Term Chemoimmunotherapy in HIV-Positive (HIV plus ) Patients (pts) with Burkitt Lymphoma (BL)
    Donarloni, Giovanni
    Re, Alessandro
    Spina, Michele
    Catfaneo, Chiara
    Fumagalli, Luca
    Mappa, Silvia
    Govi, Silvia
    Rossi, Giuseppe
    Tirelli, Umberto
    Ferreri, Andres J. M.
    BLOOD, 2011, 118 (21) : 1156 - 1157
  • [2] SAFETY AND ACTIVITY OF INTENSIVE SHORT-TERM CHEMOIMMUNOTHERAPY IN HIV-POSITIVE PATIENTS WITH BURKITT LYMPHOMA
    Donadoni, G.
    Ventre, M. Bruno
    Re, A.
    Spina, M.
    Cattaneo, C.
    Fumagalli, L.
    Foppoli, M.
    Mappa, S.
    Govi, S.
    Rossi, G.
    Tirelli, U.
    Caligaris-Cappio, F.
    Ferreri, A. J. M.
    HAEMATOLOGICA, 2012, 97 : 320 - 321
  • [3] Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma
    Ferreri, Andres J. M.
    Ventre, Marta Bruno
    Donadoni, Giovanni
    Cattaneo, Chiara
    Fumagalli, Luca
    Foppoli, Marco
    Mappa, Silvia
    Govi, Silvia
    Di Nicola, Massimo
    Rossi, Giuseppe
    Tirelli, Umberto
    Caligaris-Cappio, Federico
    Spina, Michele
    Re, Alessandro
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 (02) : 252 - 255
  • [4] A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial
    Ferreri, Andres J. M.
    Cattaneo, Chiara
    Lleshi, Arben
    Verga, Luisa
    Allione, Bernardino
    Facchetti, Fabio
    Ponzoni, Maurilio
    Foppoli, Marco
    Ferrari, Daris
    Rigacci, Luigi
    Pecciarini, Lorenza
    Donadoni, Giovanni
    Fumagalli, Luca
    Sassone, Marianna
    Calimeri, Teresa
    Rossi, Giuseppe
    Spina, Michele
    Re, Alessandro
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (01) : 119 - 128
  • [5] Incorporation of rituximab and liposomal doxorubicin into CODOX-m/IVAC for HIV-negative and HIV-positive adult patients (pts) with untreated Burkitt's lymphoma (BL): Preliminary results of a multicenter phase II study
    Gregory, S. A.
    Barr, P. M.
    Nabhan, C.
    Nukala, A.
    Gallot, L.
    Larsen, A.
    Moll, M. Z.
    Smith, S. E.
    Gordon, L. I.
    Evens, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] SAFETY AND EFFICACY OF THE "CARMEN" REGIMEN, A NEW DOSE-DENSE SHORT-TERM THERAPY, IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA AND MYC REARRANGEMENT. A MULTICENTER ITALIAN EXPERIENCE
    Angelillo, P.
    Erbella, F.
    Liberatore, C.
    Cattaneo, C.
    Verga, L.
    Lleshi, A.
    Allione, B.
    Facchetti, F.
    Ponzoni, M.
    Pagani, C.
    Foppoli, M.
    Pecciarini, L.
    Sassone, M.
    Steffanoni, S.
    Flospergher, E.
    Rossi, G.
    Spina, M.
    Re, A.
    Ferreri, A. J. M.
    HAEMATOLOGICA, 2021, 106 (10) : 138 - 138
  • [7] Dose-dense BEP (ddBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): Safety results of phase II trial
    Tryakin, Alexey
    Fedyanin, Mikhail
    Sergeev, Urii
    Bulanov, Anatoly
    Ahmedov, Bahrom
    Zakharova, Tatiana
    Mitin, Andrey
    Feinstein, Igor
    Garin, August
    Tjuiandin, Sergei
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Feasibility and Toxicity of a Modified Dose Intensive R- CODOX-M/IVAC for HIV-Associated Burkitt and Atypical Burkitt Lymphoma(BL): Preliminary Results of a Prospective Multicenter Phase II Trial of the AIDS Malignancy Consortium (AMC)
    Noy, Ariela
    Kaplan, Lawrence
    Lee, Jeannette
    BLOOD, 2009, 114 (22) : 1415 - 1416
  • [9] Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults Results from a phase II randomized controlled trial
    Kumarasamy, Nagalingeswaran
    Poongulali, Selvamuthu
    Beulah, Faith Esther
    Akite, Elaine Jacqueline
    Ayuk, Leo Njock
    Bollaerts, Anne
    Demoitie, Marie-Ange
    Jongert, Erik
    Ofori-Anyinam, Opokua
    Van der Meeren, Olivier
    MEDICINE, 2018, 97 (45)
  • [10] Post-transplant-cyclophosphamide and short-term Everolimus as graft-versus-host-prophylaxis in patients with relapsed/refractory lymphoma and myeloma-Final results of the phase II OCTET-EVER trial
    Richardson, Tim
    Scheid, Christof
    Herling, Marco
    Frenzel, Lukas P.
    Herling, Carmen
    Aguilar, Marta Rebecca Cruz
    Theurich, Sebastian
    Hallek, Michael
    Holtick, Udo
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (02) : 163 - 171
12